Pfizer | Jotup

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on:

Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points:

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on:

Wednesday, February 28, 2024

Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Retrieved on:

Wednesday, February 28, 2024

Pfizer, Infection, MDR, FDA, Food, Trial of the century, Prevalence, Safety, Fungal infection, Therapy, Pharmacokinetics, Disease, Gram-negative bacteria, Patient, IND, Mortality, VABP, Pharmaceutical industry

SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.

Key Points:

SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.
"Clearance of this IND is an important milestone in our SPR206 development program, as we prepare to advance this drug candidate into a Phase 2 trial in HABP/VABP," said Kamal Hamed, Spero’s Chief Medical Officer.
"HABP/VABP are serious infections associated with high mortality and substantial morbidity, and their management has been complicated by the increasing prevalence of difficult-to-treat and MDR Gram-negative pathogens.
SPR206 is subject to a license agreement with Pfizer Inc., which was made alongside Pfizer’s $40 million equity investment in Spero, previously announced in June 2021.

Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO

Retrieved on:

Wednesday, February 28, 2024

Pfizer, Chemistry, Bausch & Lomb, Novartis, Doctor of Philosophy, University, Therapy, Boots (company), NCX, Corporation, Glaucoma, Kowa, Partnership, Management

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.

Key Points:

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.
“I am delighted to welcome Gavin Spencer to his new role as CEO of Nicox.
Gavin brings exhaustive industry experience, particularly related to strategic partnership agreements and financing.
During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on:

Tuesday, February 27, 2024

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points:

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
Business highlights from the fourth quarter and subsequent weeks included the following:
ModeX advanced its antiviral and immune-oncology product pipeline.
Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.

DEADLINE ALERT for MSS, ASRT, DADA, BNTX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on:

Tuesday, February 27, 2024

Pfizer–BioNTech COVID-19 vaccine, Pfizer, Suite, The Company, BioNTech, Spectrum, Investment, Class, Marketing, Telephone, Sale, Risk, COVID-19, EB-5, Law, Supermarket

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points:

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
Investors have until the deadlines listed below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
Law Offices of Howard G. Smith

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on:

Tuesday, February 27, 2024

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points:

Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on:

Tuesday, February 27, 2024

Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points:

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
For more information on the ADM class action go to: https://bespc.com/cases/ADM

BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE

Retrieved on:

Monday, February 26, 2024

Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, ADS, Cancer, Court, Biotechnology, News, Advertising, Complaint, District court, Risk, COVID-19, BNTX, Infection, Defendant, Security (finance)

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points:

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on:

Monday, February 26, 2024

Nexus, Pfizer–BioNTech COVID-19 vaccine, Pfizer, Suite, The Company, BioNTech, Investment, Marketing, Risk, COVID-19, Law, Defendant, Security (finance)

LOS ANGELES, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points:

LOS ANGELES, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
Investors have until the deadlines listed below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
The Law Offices of Frank R. Cruz, Los Angeles